Norges Bank
RPRX icon

Norges Bank’s Royalty Pharma RPRX Stock Holding History

Norges Bank’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299M Buy
+5,336,084
New +$278M 0.03% 427
2026
Q1 		– Sell
-3,414,165
Closed -$132M – 1122
2025
Q4 		$132M Buy
+3,414,165
New +$130M 0.01% 648
2025
Q3 		– Sell
-5,034,369
Closed -$181M – 1245
2025
Q2 		$181M Buy
5,034,369
+140,553
+3% +$4.66M 0.02% 506
2025
Q1 		$152M Buy
4,893,816
+13,470
+0.3% +$427K 0.02% 528
2024
Q4 		$124M Buy
4,880,346
+71,003
+1% +$1.88M 0.02% 600
2024
Q3 		$136M Hold
4,809,343
– – 0.02% 575
2024
Q2 		$127M Buy
4,809,343
+309,282
+7% +$8.57M 0.02% 560
2024
Q1 		$137M Buy
4,500,061
+237,325
+6% +$7M 0.02% 554
2023
Q4 		$120M Buy
4,262,736
+126,399
+3% +$3.47M 0.02% 543
2023
Q3 		$112M Buy
4,136,337
+39,186
+1% +$1.16M 0.02% 535
2023
Q2 		$126M Sell
4,097,151
-270,557
-6% -$9.16M 0.02% 514
2023
Q1 		$157M Buy
4,367,708
+551,351
+14% +$20.4M 0.03% 433
2022
Q4 		$151M Buy
3,816,357
+318,753
+9% +$13.3M 0.04% 426
2022
Q3 		$141M Buy
3,497,604
+104,107
+3% +$4.45M 0.04% 411
2022
Q2 		$143M Buy
3,393,497
+322,101
+10% +$13.2M 0.04% 417
2022
Q1 		$120M Buy
3,071,396
+111,156
+4% +$4.36M 0.03% 524
2021
Q4 		$118M Buy
2,960,240
+99,510
+3% +$3.87M 0.02% 549
2021
Q3 		$103M Buy
2,860,730
+65,778
+2% +$2.56M 0.02% 599
2021
Q2 		$115M Buy
2,794,952
+31,815
+1% +$1.35M 0.02% 584
2021
Q1 		$121M Buy
2,763,137
+1,740,566
+170% +$82.5M 0.03% 569
2020
Q4 		$51.2M Buy
1,022,571
+300,208
+42% +$12.7M 0.01% 956
2020
Q3 		$30.4M Sell
722,363
-1,580,145
-69% -$67.8M 0.01% 1156
2020
Q2 		$112M Buy
+2,302,508
New +$114M 0.03% 464

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank's RPRX Position: Q2 2026 in Review

Norges Bank opened a new position in Royalty Pharma (RPRX) in Q2 2026: 5,336,084 shares worth $299M. The stake represents 0.03% of the portfolio and ranks #427 among its holdings. This is a return to the name: Norges Bank previously reported a position in RPRX as recently as Q4 2025.

Norges Bank first reported a position in RPRX in Q2 2020 and has held it in 23 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Norges Bank held 5,336,084 shares of Royalty Pharma worth $299M as of Q2 2026.
  • Royalty Pharma was a new Norges Bank position in Q2 2026.
  • Royalty Pharma made up 0.03% of Norges Bank's portfolio in Q2 2026, its #427 holding.
  • Norges Bank first reported a position in Royalty Pharma in Q2 2020 and has held it in 23 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.